The lab analyst performs a genomic sequence analysis panel to evaluate the patient tumor specimen for DNA and RNA sequence variants, copy number variants, and rearrangements known to impact diagnosis and treatment of solid organ cancers. The test also evaluates other factors that may guide treatment options, such as microsatellite instability (MSI), which is an indicator of how likely the cells are to mutate, and tumor mutation burden (TMB), which is an indicator of the level of genetic mutations present in cancer cells.
For clinical responsibility, terminology, tips and additional info
start codify free trial.